Arc - You can't compare the phase-II and -III like that.
The phase-II was an open label study with all the biases that come along with knowledge of who is on the experimental therapy. This impacts both patients and clinicians. The phase-III was double blind and is therefore better controlled for biases.
The phase-III readout is a much more reliable indicator of efficacy than the phase-II.
hunter hall, page-2
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable